REQUIP SUMMARY
Requip (ropinirole hydrochloride), an orally administered anti-Parkinsonian drug, is a non-ergoline dopamine agonist.
Requip (ropinirole hydrochloride) is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
|
NEWS HIGHLIGHTSMedia Articles Related to Requip (Ropinirole)
Hope For Possible Parkinson's Disease Cure From ISU Researchers' Findings
Source: Seniors / Aging News From Medical News Today [2009.11.04]
Researchers at Iowa State University have found an essential key to possibly cure Parkinson's disease and are looking for others. Anumantha Kanthasamy, a distinguished professor of biomedical sciences and W. Eugene and Linda R. Lloyd Endowed Chair in Neurotoxicology at the ISU College of Veterinary Medicine, has been working to understand the complex mechanisms of the disease for more than a decade and thinks he has found hope for the cure.
Less Invasive Stereotactic Radiosurgery As Effective In Eliminating Parkinson's Disease Tremors As Other Treatments
Source: Medical Devices / Diagnostics News From Medical News Today [2009.11.03]
Stereotactic radiosurgery (SRS) offers a less invasive way to eliminate tremors caused by Parkinson's disease and essential tremor than deep brain stimulation (DBS) and radiofrequency (RF) treatments, and is as effective, according to a long-term study presented November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Progression Of Parkinson's Disease May Be Prevented By Widely Used Cholesterol-Lowering Drug
Source: Statins News From Medical News Today [2009.10.31]
Simvastatin, a commonly used, cholesterol-lowering drug, may prevent Parkinson's disease from progressing further. Neurological researchers at Rush University Medical Center conducted a study examining the use of the FDA-approved medication in mice with Parkinson's disease and found that the drug successfully reverses the biochemical, cellular and anatomical changes caused by the disease.
Avian Influenza Strain Primes Brain For Parkinson's Disease
Source: Bird Flu / Avian Flu News From Medical News Today [2009.08.11]
At least one strain of the H5N1 avian influenza virus leaves survivors at significantly increased risk for Parkinson's disease and possibly other neurological problems later in life, according to new research from St. Jude Children's Research Hospital.
Parkinson's Disease
Source: MedicineNet Amyotrophic Lateral Sclerosis Specialty [2009.04.28]
Title: Parkinson's Disease
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 4/28/2009
Published Studies Related to Requip (Ropinirole)
Randomized, placebo-controlled, double-blind study of ropinirole in chronic stroke. [2009.09]
BACKGROUND AND PURPOSE: Evidence suggests the potential to improve motor status in patients with stroke by modifying brain catecholaminergic tone. The current study hypothesized that increased dopaminergic tone via the dopamine agonist ropinirole, when combined with physiotherapy (PT), would significantly and safely increase gait velocity... CONCLUSIONS: At doses achieved in this trial, increased dopaminergic tone via ropinirole+PT was generally well tolerated but did not show any improvement over and above the effects of PT alone.
Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease. [2009.05]
OBJECTIVES: To explore the pharmacokinetic-pharmacodynamic relationship between systemic exposure to ropinirole and the primary efficacy end points from two phase 3 studies... CONCLUSIONS: Characterization of the exposure-response relationship has identified that a dose range of 8 to 12 mg provides clinical benefit for the improvement in UPDRS total motor score in patients with early PD. Similarly, pharmacokinetic-pharmacodynamic analysis showed that, in patients with advanced PD, the probability of response increased with increasing exposures to ropinirole, indicating that doses more than 8 to 12 mg may lead to an improved benefit in parallel with reductions in L-dopa dose.
Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. [2009.03]
STUDY OBJECTIVE: To compare the effects of ropinirole with those of placebo on sleep, as evaluated by specific domains of the Medical Outcomes Study (MOS) sleep scale, as well as the Clinical Global Impression-Improvement (CGI-I) scale, in patients with restless legs syndrome (RLS)... CONCLUSION: Pooled data from six similarly designed clinical trials provide evidence that ropinirole improves sleep quantity and adequacy, and lessens sleep disturbance and daytime somnolence in patients with primary RLS.
Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. [2007.12]
Rotigotine is a new, non-ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate the efficacy and safety of the rotigotine transdermal patch in the treatment of early Parkinson's disease... In conclusion, the rotigotine transdermal patch represents an effective and safe option for the treatment of patients with early Parkinson's disease.
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. [2007.12]
In a 5-year, double-blind study, subjects with Parkinson's disease (PD) who were randomized to initial treatment with ropinirole had a significantly lower incidence of dyskinesia compared with subjects randomized to levodopa, although Unified Parkinson's Disease Rating Scale (UPDRS) motor scores were significantly more improved in the levodopa group...
Clinical Trials Related to Requip (Ropinirole)
A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's [Completed]
This study was designed to compare the effectiveness and tolerability of a new prolonged
release formulation of ropinirole with the currently marketed immediate release formulation
which is prescribed in many countries. The new prolonged release formulation allows the drug
to be taken once a day rather than three times a day. This study will also evaluate the side
effects of the new prolonged release formulation of ropinirole
Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome) [Completed]
Treating Sexual Dysfunction From SSRI Medication: a Study Comparing Requip CR to Placebo [Active, not recruiting]
Antidepressant medicines sometimes cause sexual side effects. The purpose of this study is to
determine whether the sexual dysfunction sometimes caused by selective serotonin reuptake
inhibitor (SSRI) antidepressant medications can be reversed by treatment with Requip
(ropinirole), a medicine which is used to treat Parkinson's Disease and restless leg
syndrome.
Long-Term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164 [Active, not recruiting]
The purpose of this study is to obtain information on the long-term safety, tolerability, and
therapeutic benefit of extended release ropinirole XL, and to provide a mechanism for
patients who participated in either Study 167 or Study 164 to continue receiving ropinirole
XL if they chose to do so.
An Open-Label Continuation Study Evaluating the Long-Term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease [Active, not recruiting]
To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with
early and advanced Parkinson's disease.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 8 ratings/reviews, Requip has an overall score of 8.50. The effectiveness score is 9.25 and the side effect score is 7.50. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
| | Requip review by 53 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | Mild Side Effects | | |
Treatment Info |
| Condition / reason: | | Restless leg syndrome |
| Dosage & duration: | | 0.5 mg taken at bedtime for the period of 2 years |
| Other conditions: | | Sleeplessness |
| Other drugs taken: | | None | | |
Reported Results |
| Benefits: | | While standing, my legs were fine, but aching, cramping legs were keeping me from getting any sleep. My doctor suggested I try Requip, and its been the best thing I have done. |
| Side effects: | | I have experienced no side effects, except sleeping at night. The warning says that it might make you drowsy, but that's also why they say to take it at night. |
| Comments: | | I take Requip about 1-1/2 to 2 hours before bedtime. It permits relaxation of legs so I can sleep. |
|
| | Requip review by 44 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | Restless legs Syndrome |
| Dosage & duration: | | 1.0 (dosage frequency: 1 pill at night) for the period of 1 year |
| Other conditions: | | None |
| Other drugs taken: | | None | | |
Reported Results |
| Benefits: | | Requip has helped me sleep at night! no more horrible creepy crawley sensations... great medication! |
| Side effects: | | None. |
| Comments: | | Take 1 pill 2 hours before bedtime. |
|
| | Requip review by 63 year old female patient | | | Rating |
| Overall rating: | | |
| Effectiveness: | | Marginally Effective |
| Side effects: | | Extremely Severe Side Effects | | |
Treatment Info |
| Condition / reason: | | RLS associated with sleep apnea |
| Dosage & duration: | | 3mg taken nightly for the period of 3 months |
| Other conditions: | | diabetes |
| Other drugs taken: | | Novalog | | |
Reported Results |
| Benefits: | | None |
| Side effects: | | Began with Requip pack and gradually increased dosage. Immediately felt more lethargic and irritable. On my third week at 3mg. I could not keep any food down in the mornings. My doctor said the sleepiness and irritability was not related to Requip. After 10 days of vomiting in the a.m I stopped the medication. Feel much better even though my doctor insists I need it.
|
| Comments: | | Gradually increased dosage. After last overnight sleep study doctor increased by dosage to 3 mg. That's when the severe nausea and then followed by vomiting. |
|
|
|
Page last updated: 2009-11-04
|
